DEF 14A: RxSight, Inc. Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

RxSight, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to vote on director elections, executive compensation, and auditor ratification.

Summary

• RxSight, Inc. will host its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, at 8:00 a.m. Pacific Time.
• Stockholders of record as of April 8, 2024, are eligible to vote.
• The meeting will address the election of three Class III directors (Julie B. Andrews, Robert J. Palmisano, and Tamara R. Fountain, M.D.) to serve until the 2027 annual meeting.
• An advisory vote will be held on the compensation of named executive officers (Say-on-Pay Vote).
• Stockholders will also vote on the frequency of future Say-on-Pay Votes.
• The ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, will be voted on.
• The Board recommends voting FOR the election of the director nominees, FOR the approval of executive compensation, FOR every one year for the frequency of Say-on-Pay votes, and FOR the ratification of Ernst & Young LLP.
• The company's common stock outstanding as of the record date was 37,173,544 shares.
• The deadline to propose actions for consideration at the next annual meeting is December 26, 2024, for inclusion in the proxy statement.
• The deadline for stockholder recommendations for director candidates is between February 6, 2025, and March 8, 2025.
• The company lost its emerging growth company and smaller reporting company status as of December 31, 2023.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting information in a neutral and factual manner. The sentiment is moderately positive as it outlines governance processes and seeks stockholder input.

Positives

• The company is providing expanded access to the Annual Meeting through a virtual format, improving communication and enabling increased stockholder attendance and participation.
• The Board is actively engaged in risk oversight, with committees responsible for overseeing specific areas of risk.
• The Board has a diverse composition, with consideration given to a broad range of backgrounds and experiences when evaluating director nominees.
• The company has stock ownership guidelines for non-employee directors to align their interests with those of stockholders.
• The company has a code of business conduct and ethics in place for directors, officers, and employees.
• The company provides annual cash incentive compensation to its named executive officers under the Company's Executive Incentive Compensation Plan based on their meeting of one or more corporate and individual performance objectives.

Negatives

• The company lost its status as an emerging growth company and smaller reporting company as of December 31, 2023, which may result in increased compliance costs and disclosure requirements.
• Dr. Link is not considered independent under Nasdaq rules due to certain payments made by the company in 2023 to a company in which a trust affiliated with Dr. Link is a minority investor and in which Dr. Link's son-in-law serves as the chief executive officer.

Risks

• The classification of the Board may have the effect of delaying or preventing changes in control of the company.
• The loss of emerging growth company status may lead to increased regulatory scrutiny and compliance costs.
• The company's success is dependent on what its management team can accomplish together.

Future Outlook

The Board intends to propose an advisory vote on the frequency of the Say-on-Pay Vote at least once every six calendar years.

Management Comments

• The Board believes that an annual Say-on-Pay Vote will facilitate more direct stockholder input about executive compensation.
• The Board believes that an annual Say-on-Pay Vote is consistent with the company's policy of reviewing its compensation program annually, as well as being accountable to its stockholders on corporate governance and executive compensation matters.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including proxy solicitations, director elections, and executive compensation disclosures. The virtual meeting format aligns with a growing trend in corporate governance to enhance accessibility and reduce costs.

Comparison to Industry Standards

• The director independence criteria align with Nasdaq listing requirements and SEC rules, similar to other publicly listed companies.
• The executive compensation program aims to be competitive with peer companies, as determined by AON/Radford, a common practice in the industry.
• The company's audit committee charter and practices are consistent with SEC regulations and Nasdaq listing standards, comparable to other publicly held entities.
• The company's equity ownership guidelines for non-employee directors are in line with industry practices to align director interests with those of stockholders.

Corporate Governance

Related Party Transactions

• Ron Kurtz, M.D., our President and Chief Executive Officer, and Longitude Prime Fund, L.P. (LPF) purchased 40,000 shares and 480,000 shares, respectively, of our common stock at a price of $12.50 per share in our follow-on public offering.
• In 2023, we made an aggregate of $641,000 in rebate payments to Praxis Management, LLC and related Praxis entities, in which a trust affiliated with director William J. Link, Ph.D. is a minority investor and in which Dr. Link's son-in-law serves as the chief executive officer.

Stakeholder Impact

• Stockholders have the opportunity to vote on key decisions, including director elections and executive compensation.
• The company's governance practices aim to align the interests of management and the Board with those of stockholders.
• Employees are impacted by the company's compensation policies and benefit plans, including the 401(k) plan.

Next Steps

• Stockholders are urged to vote on the proposals outlined in the proxy statement.
• The company will file a Current Report on Form 8-K to announce the voting results within four business days after the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Director Election, Ernst & Young, Corporate Governance, RxSight